P8IP
DNLI icon

Pier 88 Investment Partners’s Denali Therapeutics DNLI Stock Holding History

Pier 88 Investment Partners’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.24M Sell
64,800
-3,400
-5% -$67.7K 0.31% 41
2025
Q4 		$1.13M Buy
68,200
+760
+1% +$12.8K 0.25% 47
2025
Q3 		$979K Buy
67,440
+10,290
+18% +$148K 0.18% 60
2025
Q2 		$800K Buy
57,150
+12,240
+27% +$172K 0.15% 65
2025
Q1 		$611K Sell
44,910
-500
-1% -$9.58K 0.12% 80
2024
Q4 		$925K Sell
45,410
-13,760
-23% -$352K 0.18% 56
2024
Q3 		$1.72M Sell
59,170
-10,200
-15% -$253K 0.38% 36
2024
Q2 		$1.61M Buy
69,370
+29,400
+74% +$564K 0.36% 42
2024
Q1 		$820K Sell
39,970
-5,270
-12% -$99K 0.2% 46
2023
Q4 		$971K Sell
45,240
-5,460
-11% -$108K 0.24% 54
2023
Q3 		$1.05M Buy
50,700
+3,020
+6% +$76.6K 0.26% 63
2023
Q2 		$1.41M Buy
47,680
+4,840
+11% +$136K 0.35% 51
2023
Q1 		$987K Buy
42,840
+7,600
+22% +$209K 0.24% 55
2022
Q4 		$980K Buy
35,240
+23,150
+191% +$689K 0.24% 54
2022
Q3 		$371K Sell
12,090
-990
-8% -$32.2K 0.09% 79
2022
Q2 		$385K Buy
13,080
+13,070
+130,700% +$342K 0.09% 85
2022
Q1 		$0 Sell
10
-33,070
-100% -$1.14M ﹤0.01% 90
2021
Q4 		$1.48M Buy
33,080
+14,200
+75% +$673K 0.31% 64
2021
Q3 		$952K Buy
18,880
+4,760
+34% +$268K 0.29% 73
2021
Q2 		$1.11M Buy
14,120
+6,560
+87% +$406K 0.32% 74
2021
Q1 		$432K Sell
7,560
-5,265
-41% -$352K 0.15% 98
2020
Q4 		$1.07M Sell
12,825
-22,970
-64% -$1.39M 0.35% 53
2020
Q3 		$1.28M Sell
35,795
-16,514
-32% -$497K 0.39% 53
2020
Q2 		$1.26M Buy
52,309
+4,609
+10% +$108K 0.36% 69
2020
Q1 		$835K Buy
47,700
+5,700
+14% +$119K 0.3% 57
2019
Q4 		$732K Buy
42,000
+1,390
+3% +$23.1K 0.29% 47
2019
Q3 		$622K Buy
40,610
+12,960
+47% +$248K 0.24% 65
2019
Q2 		$574K Sell
27,650
-8,280
-23% -$186K 0.24% 70
2019
Q1 		$834K Buy
35,930
+9,800
+38% +$205K 0.38% 48
2018
Q4 		$540K Sell
26,130
-11,800
-31% -$214K 0.27% 52
2018
Q3 		$825K Buy
+37,930
New +$627K 0.36% 41

Other funds holding DNLI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Pier 88 Investment Partners's DNLI Position: Q1 2026 in Review

Pier 88 Investment Partners reduced its Denali Therapeutics (DNLI) stake by 5% in Q1 2026, selling an estimated $67.7K and leaving 64,800 shares worth $1.24M. The position accounts for 0.31% of the portfolio, ranked #41.

Pier 88 Investment Partners first reported a position in DNLI in Q3 2018 and has held it in 31 quarters since. The position peaked at $1.72M in Q3 2024. 268 funds tracked by Wall St. Rank hold DNLI as of Q1 2026.

  • Pier 88 Investment Partners held 64,800 shares of Denali Therapeutics worth $1.24M as of Q1 2026.
  • Pier 88 Investment Partners sold 3,400 Denali Therapeutics shares in Q1 2026, an estimated $67.7K.
  • Denali Therapeutics made up 0.31% of Pier 88 Investment Partners's portfolio in Q1 2026, its #41 holding.
  • Pier 88 Investment Partners first reported a position in Denali Therapeutics in Q3 2018 and has held it in 31 quarters since.
  • Pier 88 Investment Partners's Denali Therapeutics position peaked at $1.72M in Q3 2024.
  • 268 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2026.

Based on Pier 88 Investment Partners's 13F filing for Q1 2026, filed 11 May 2026.